Development and characterization of PLGA nanoparticles as delivery systems of a prodrug of zidovudine obtained by its conjugation with ursodeoxycholic acid

References

• Bala I, Hariharan S, Kumar MN. (2004). PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 21:387–422
   PubMed Web of Science ®Google Scholar
• Batrakov EV, Kabanov AB. (2008). Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Contr Rel 130:98–106
   PubMed Web of Science ®Google Scholar
• Carter CA, Ehrlich LS. (2008). Cell biology of HIV-1. Infection of macrophages. Annu Rev Microbiol 62:425–33
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang C, Liu Q, et al. (2012). Solanum tuberosum lectin-conjugated PLGA nanoparticles for nose-to-brain delivery: in vivo and in vitro evaluations. J Drug Target 20:174–84
   PubMed Web of Science ®Google Scholar
• Childs CE. (1975). Determination of polyoxyethylen glycol in gammaglobulin solutions. Microchem J 20:190–2
   Web of Science ®Google Scholar
• Chorny M, Fishbein I, Danenberg HD, Golomb G. (2002). Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Contr Rel 83:389–400
   PubMed Web of Science ®Google Scholar
• Contado C, Argazzi R. (2009). Size sorting of citrate reduced gold nanoparticles by sedimentation field-flow fractionation. J Chromatogr A 1216:9088–98
   PubMed Web of Science ®Google Scholar
• Contado C, Argazzi R. (2011). Sedimentation field flow fractionation and flow field flow fractionation as tools for studying the aging effects of WO3 colloids for photoelectrochemical uses”. J Chromatogr A 1218:4179–87
   PubMed Web of Science ®Google Scholar
• Contado C, Vighi E, Dalpiaz A, Leo E. (2013). Influence of secondary preparative parameters and aging effects on PLGA particle size distribution: a sedimentation field flow fractionation investigation. Anal Bioanal Chem 405:703–11
   PubMed Web of Science ®Google Scholar
• Dalpiaz A, Cacciari B, Mezzena M, et al. (2010). Solid lipid microparticles for the stability enhancement of a dopamine prodrug. J Pharm Sci 99:4730–7
   PubMed Web of Science ®Google Scholar
• Dalpiaz A, Leo E, Vitali F, et al. (2005). Development and characterization of biodegradable nanoparticles as delivery systems of antiischemic adenosine derivatives. Biomaterials 26:1299–306
   PubMed Web of Science ®Google Scholar
• Dalpiaz A, Mezzena M, Scatturin A, Scalia S. (2008). Solid lipid microparticles for the stability enhancement of the polar drug N(6)-cyclopentyladenosine. Int J Pharm 355:81–6
   PubMed Web of Science ®Google Scholar
• Dalpiaz A, Scatturin A, Menegatti E, et al. (2001). Synthesis and study of 5′-ester prodrugs of N6-cyclopentyladenosine, a selective A1 receptor agonist. Pharm Res 18:531–6
   PubMed Web of Science ®Google Scholar
• Dalpiaz A, Scatturin A, Pavan B, et al. (2002). Poly (lactic acid) microspheres for the sustained release of antiischemic agents. Int J Pharm 242:115–20
   PubMedGoogle Scholar
• Dalpiaz A, Vighi E, Pavan B, Leo E. (2009). Fabrication via a nonaqueous nanoprecipitation method, characterization and in vitro biological behaviour of N6-cyclopentyladenosine-loaded nanoparticles. J Pharm Sci 98:4272–84
   PubMed Web of Science ®Google Scholar
• Dalpiaz A, Paganetto G, Pavan B, et al. (2012). Zidovudine and ursodeoxycholic acid conjugation: design of a new prodrug potentially able to bypass the active efflux transport systems of the central nervous system. Mol Pharmaceutics 9:957–68
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. (2012). PLGA-based nanoparticles: an overview of biomedical applications. J Contr Rel 161:505–22
   PubMed Web of Science ®Google Scholar
• Davis LE, Hjelle BL, Miller VE, et al. (1992). Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 42:1736–9
   PubMed Web of Science ®Google Scholar
• De Clerk E. (2009). Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33:307−20
   PubMed Web of Science ®Google Scholar
• Fessi H, Puisieux F, Devissaguet JP, et al. (1989). Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55:R1–4
   Web of Science ®Google Scholar
• Gelperin S, Maksimenko O, Khalansky A, et al. (2010). Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm 74:157–63
   PubMed Web of Science ®Google Scholar
• Gray F, Scaravilli F, Everall I, et al. (1996). Neuropathology of early HIV-1 infection. Brain Pathol 6:1–15
   PubMed Web of Science ®Google Scholar
• Hunter RJ. (1989). Foundations of colloid science, vol I. Oxford, New York: Oxford University Press
   Google Scholar
• Jalil R. (1990). Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) polymers in sustained drug delivery. Drug Dev Ind Pharm 16:2353–67
   Web of Science ®Google Scholar
• Johansen P, Men Y, Merkle HP, Gander B. (2000). Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 50:129–46
   PubMed Web of Science ®Google Scholar
• Kolson DL, Gonzales Sacrano F. (2000). HIV and HIV dementia. J Clin Invest 106:11--13
   Google Scholar
• Leo E, Contado C, Bortolotti F, et al. (2006a). Nanoparticle formulation may affect the stabilization of an antischemic prodrug. Int J Pharm 307:103–13
   PubMedGoogle Scholar
• Leo E, Scatturin A, Vighi E, Dalpiaz A. (2006b). Polymeric nanoparticles as drug controlled release systems: a new formulation strategy for drugs with small or large molecular weight. J Nanosci Nanotechnol 6:3070–9
   PubMed Web of Science ®Google Scholar
• Liang V. (1987). Multidrug resistance P-glycoprotein expression. Ann NY Acad Sci 507:7–8
   PubMed Web of Science ®Google Scholar
• Lobato M, et al. (2012). Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies. Int J Nanomedicine 7:5793--806
   Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the folin phenol reagent. J Biol Chem 193:265–75
   PubMed Web of Science ®Google Scholar
• Makadia HK, Siegel SJ. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 3:1377–97
   PubMed Web of Science ®Google Scholar
• Nafee N, Schneider M, Schaefer UF, Lehr CM. (2009). Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile. Int J Pharm 38:130–9
   Google Scholar
• Owens DE III, Peppas NA. (2006). Opsonization, biodisribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93–102
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2003). Blood-brain barrier drug targeting: the future of brain drug development. Mol Interventions 3:90–105
   PubMedGoogle Scholar
• Siepmann J, Faisant N, Akiki J, et al. (2004). Effect of the size of biodegradable microparticles on drug release: experiment and theory. J Control Release 96:123–34
   PubMed Web of Science ®Google Scholar
• Takasawa K, Terasaki T, Suzuki H, Sugiyama Y. (1997). In vivo evidence for carrier-mediated efflux transport of 3′-Azido-3′- deoxythymidine and 2′,3′-dideoxyinosine across the blood-brain barrier via a probenecid sensitive transport system. J Pharmacol Exp Ther 281:369–75
   PubMed Web of Science ®Google Scholar
• Tomoda K, Watanabe A, Suzuki K, et al. (2012). Enhanced transdermal permeability of estradiol using combination of PLGA nanoparticles system and iontophoresis. Colloids Surf B Biointerfaces 97:84–9
   PubMed Web of Science ®Google Scholar
• Vyas SP, Subhedar R, Jain S. (2006). Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. J Pharm Pharmacol 58:321–6
   PubMed Web of Science ®Google Scholar
• Wong SL, Van Belle K, Sawchuk RJ. (1993). Distributional transport kinetics of zidovudine between plasma and brain extracellular Fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis. J Pharmacol Exp Ther 264:899–909
   PubMed Web of Science ®Google Scholar